Neuronal voltage-gated calcium channel (VGCC)

Neuronal voltage-gated calcium channels (VGCCs) are essential transmembrane proteins that mediate the influx of calcium ions into neurons in response to membrane depolarization [1]. They are classified into high-voltage activated (HVA) channels, including N-type (Cav2.2), P/Q-type (Cav2.1), and R-type (Cav2.3), and low-voltage activated (LVA) T-type channels (Cav3.1-3.3) [2]. These channels serve as the primary link between electrical signaling and biochemical action, triggering the release of neurotransmitters at presynaptic terminals and regulating neuronal excitability and gene expression [1, 3]. Dysregulation or genetic mutations in VGCCs are implicated in a wide range of neurological conditions, such as chronic neuropathic pain, absence epilepsy, and familial hemiplegic migraine [2, 5]. Therapeutic strategies involve subtype-specific inhibition to attenuate aberrant signaling, such as the use of Ziconotide for severe pain or gabapentinoids for modulating the alpha2-delta auxiliary subunit in epilepsy and anxiety [4]. Given their diverse roles across the central and peripheral nervous systems, they remain high-priority targets for precision medicine in neurology and psychiatry.

Other names

Voltage-dependent calcium channelCav channelN-type calcium channelP/Q-type calcium channelR-type calcium channelT-type calcium channelVoltage-gated Ca2+ channel

Drugs targeting these channels typically act by direct pore blockade of the alpha1 subunit (e.g., Ziconotide for Cav2.2) or by binding to auxiliary subunits such as alpha2-delta (e.g., Gabapentinoids) to inhibit channel trafficking and reduce calcium-dependent neurotransmitter release [2, 4]. T-type channel blockers (e.g., Ethosuximide) reduce low-threshold calcium spikes to stabilize neuronal firing in epilepsy [1].